We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Issues Final No on Aduhelm, Recommending Biogen Speed Confirmatory Trial and Drop Price by Up to 95 Percent
ICER Issues Final No on Aduhelm, Recommending Biogen Speed Confirmatory Trial and Drop Price by Up to 95 Percent
The Institute for Clinical and Economic Review (ICER) issued its final word on Biogen’s newly approved and very controversial $56,000-a-year Alzheimer’s drug Aduhelm (aducanumab) Thursday, and that word is “no.”